Macupatide

Macupatide is a gastric inhibitory peptide (GIP) receptor agonist used in anti-diabetic research[1].

2923558-68-1

LY3532226

12352209

Insulin Receptor

Protein Tyrosine Kinase/RTK

Metabolism-protein/nucleotide metabolism

Metabolic Disease

99.71

DMSO : 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

O=C([C@@H](N)CC1=CC=C(O)C=C1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@](C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N3[C@H](C(N4[C@H](C(N5[C@H](C(N[C@H](C(N)=O)CO)=O)CCC5)=O)CCC4)=O)CCC3)=O)C)=O)=O)CO)=O)CO)=O)CCC2)=O)=O)C)=O)CCC(O)=O)=O)CC(C)C)=O)CC(C)C)=O)CC6=CC=NC=C6)=O)CCC(O)=O)=O)C(C)C)=O)CC7=CC=CC=C7)=O)CC(O)=O)=O)C)=O)CCC(N)=O)=O)CC8=CNC=N8)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)CC(C)C)=O)[C@H](CC)C)=O)CO)=O)CC9=CC=C(O)C=C9)=O)CC(O)=O)=O)CO)=O)[C@H](CC)C)=O)CC%10=CC=CC=C%10)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C

C232H357N49O72

4984.60

[1]WHO. International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed International Nonproprietary Names: List 132. WHO Drug Information, Vol. 38 , No. 4, 2024.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10959/Macupatide-SDS-MedChemExpress.pdf

Peptides

Phase 1